Study Summary
This trial is testing a new drug, NTX-301, to see if it can help people with myeloid malignancies (a type of cancer). The drug is taken orally, and has shown promise in earlier studies.
- Acute Myeloid Leukemia
- Chronic Myelomonocytic Leukemia
- Myelodysplastic Syndrome
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 9 Secondary · Reporting Duration: 3 years
Trial Safety
Safety Progress
Trial Design
1 Treatment Group
NTX-301
1 of 1
Experimental Treatment
20 Total Participants · 1 Treatment Group
Primary Treatment: NTX-301 · No Placebo Group · Phase 1
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · Male Participants · 7 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
Has NTX-301 been granted clearance from the FDA?
"There is scant evidence regarding the security of NTX-301, so it earned a score of 1." - Anonymous Online Contributor
Has recruitment for this clinical trial commenced?
"According to clinicaltrials.gov, this medical study is now in the process of enrolling participants. This research initiative was first published on June 1st 2021 and had its most recent update on December 6th 2021." - Anonymous Online Contributor
What is the estimated sample size for this clinical research?
"Affirmative, clinicaltrials.gov reflects that this research is actively seeking volunteers. It was initially made available on January 6th 2021 and the most recent update occurred on December 6th 2021. This study requires 20 participants from a single medical centre to be recruited." - Anonymous Online Contributor